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Introduction
Mesial temporal lobe epilepsy (MTLE), one of the most common forms of drug-resistant focal epilepsies, impairs quality-of-life, can progressively impair cognition and mental health, and can be fatal due to sudden death in epilepsy (SUDEP) or other causes (e.g., status epilepticus, accidents) (Bell et al., 2011; Devinsky et al., 2016) .
Hippocampal sclerosis is the most prevalent neuropathological finding in patients with drug-resistant MTLE and is characterized by neuronal loss, atrophy, inelasticity/hardness, and astroglial proliferation in the hippocampus (Blümcke et al., 2013; Thom, 2004) . Surgical resection is a common treatment for MTLE patients, but complication can arise. Overall, surgery is effective in approximately 60% of cases, however, 25-35% of MTLE patients do not achieve sustained seizure freedom and some suffer cognitive and behavioral sequelae (Blumcke et al., 2017; Dredla et al., 2016; Engel et al., 2012; Kang et al., 2016; Pruitt et al., 2016) . Moreover, many patients are not candidates for surgery. Thus, there is an urgent need to better understand the molecular mechanisms underlying MTLE to develop novel molecular-based therapies.
Previous transcriptional studies of hippocampal tissue from MTLE patients identified profound changes in gene expression; however, the studies examined only one brain region, analyzed selective transcriptomic elements or were under-powered (Dixit et al., 2016; Griffin et al., 2016; Kaalund et al., 2014) . Studies profiling differentially expressed mRNA and microRNAs (miRNAs) in animal MTLE studies are limited by heterogeneous seizure/epilepsy models and strains, leading to discordant results (Korotkov et al., 2017) . Further, no study has analyzed other short non-coding RNAs elements of the transcriptome such as small nuclear RNAs or small nucleolar RNAs. These elements of the transcriptome represent important regulatory elements that are thought to play a critical role in cancer prognosis (Liao et al., 2010; Mei et al., 2012) , but have not been studied in the context of MTLE. Performing RNA-Seq and small RNA-Seq on clinically well-characterized brain tissue resected during J o u r n a l P r e -p r o o f surgical treatment of drug-resistant MTLE patients offers a unique opportunity to assay all elements of the transcriptome towards developing a better understanding of the molecular mechanisms underlying the pathogenesis of MTLE.
In this study, we comprehensively analyzed all transcriptomic elements in parallel in fresh-frozen cortical and hippocampal tissue resected at surgery from MTLE patients using both RNA-Seq and small RNA-Seq. Using RNA-Seq we identified marked changes in the hippocampus of the MTLE patients when compared to controls but not in the cortex of MTLE patients. By contrast, small RNA-Seq revealed striking differences in the expression of miRNAs as well as other small non-coding RNAs in both the cortex and hippocampus of MTLE patients.
Integration of the small RNA and mRNA transcriptomic profiles of the MTLE-HS identified 36 significantly enriched pathways that may be regulated by miRNAs, including many immune response and inflammation related pathways.
Materials and Methods

Human tissue
The MTLE surgical tissue analyzed in this study was obtained from the archives of the departments of (Neuro)pathology of the Amsterdam University Medical Centers (Amsterdam UMC), the Netherlands, and University College London (UCL), United Kingdom. Informed consent was obtained from each Institutional Review Board (Amsterdam UMC and UCL) to use brain tissue and to access medical records. Tissue was used in accordance with the Declaration of Helsinki and the Amsterdam UMC Research Code provided by the Medical Ethics Committee and approved by the scientific committee of the university Biobank. For this study, 11 postmortem control samples (5 cortical and 6 hippocampal) and 22 surgical MTLE samples (6 cortical and 16 hippocampal) were obtained. Table 1 summarizes the clinical characteristics of the patients and controls. All cases were reviewed independently by two neuropathologists and the classification of hippocampal sclerosis was based on International League Against Epilepsy criteria for microscopic examination (Blümcke et al., 2013) . Control material was obtained during autopsy of age-matched individuals without a history of seizures or other neurological diseases. J o u r n a l P r e -p r o o f MTLE-4  cortex  Male  11  15  26   MTLE-5  cortex  Female  23  9  32   MTLE-6  cortex  Male  52  0  52   MTLE-7  cortex  Male  15  7  22   MTLE-1  hippocampus  Female  11  22  32   MTLE-3  hippocampus  Male  9  21  29   MTLE-5  hippocampus  Female  23  9  32   MTLE-6  hippocampus  Male  52  0 Control -1  cortex  Male  --31   Control-4  cortex  Male  --31   Control-6  cortex  Male  --49   Control-7  cortex  Male  --57   Control-8  cortex  Male  --48   Control-1  hippocampus  Male  --31   Control-2  hippocampus  Male  --25   Control-3  hippocampus  Female  --44   Control-4  hippocampus  Male  --31   Control-5  hippocampus  Male  --75   Control-6  hippocampus  Male  --49 J o u r n a l P r e -p r o o f Cambridgeshire, UK) and Trimmomatic v0.36 to filter reads of low quality (Bolger et al., 2014) . Low quality leading and trailing bases were removed from each read, a sliding window trimming using a window of four and a phred33 score threshold of 15 to assess the quality of the read body. Any read <17 nts was discarded. Both forward and reverse reads had to be present for reads to be included in downstream analysis.
Reads were aligned to the human reference genome, GRCh38 using Bowtie2 version 2.3.2 (Langmead and Salzberg, 2012) , no mismatches between the seed sequence and the reference genome were allowed, reads were allowed to align a maximum of ten times. Using the featureCounts program from the Subread package the number of reads that aligned to the miRNAs, according to miRBase21 (Griffiths-Jones et al., 2008; Kozomara and GriffithsJones, 2014 ) (www.mirbase.org) and other short RNA species extracted from Gencode v27 were calculated (Harrow et al., 2012; Kozomara and Griffiths-Jones, 2014; Liao et al., 2014) . Small RNAs with >=5 read counts in >=4 samples were considered expressed. Differential expression analysis was performed using the R package DESeq2 (Love et al., 2014) . The false discovery rate was controlled for using the Benjamini-Hochberg correction, gene expression changes with an adjusted p-value<0.05 were considered statistically significant.
Integrative bioinformatics
RNA-Seq and small RNA-Seq data was integrated using the R package "piano" (Väremo et al., 2013) and custom scripts written in R. The "piano" package is an open source tool available in R that can be used to perform gene set enrichment analysis (GSEA) using a variety of methods. The whole RNA transcriptome profile and the Reactome (Croft et al., 2011; Fabregat et al., 2018) gene to pathway dataset were fed to "piano". The Wilcoxon rank-sum test method was used to identify enriched gene-sets amongst the dataset. Significance values were calculated through random gene sampling. First, a random set of genes equal in size to the gene-set being tested was selected and the gene set statistic was recalculated (Väremo et al., 2013) . This was repeated 10,000 times to give a discrete null distribution. The gene set p-value was based on the fraction of random gene set statistics equal to or more extreme than the original gene set statistic. All p-values were corrected using the Benjamini-Hochberg method. Gene sets with an adjusted p-value <0.05 were considered enriched. Next, gene sets enriched for differentially expressed genes were identified using Fisher's exact test. Gene sets with a Benjamini-Hochberg adjusted p-value<0.05 were considered enriched for differentially expressed genes. Results were visualized using Cytoscape (Shannon et al., 2003) .
Gene sets that were potentially modulated by miRNAs were then identified. First, the list of validated J o u r n a l P r e -p r o o f miRNA targets for each of the differentially expressed miRNAs was retrieved from miRWalk2 (Dweep et al., 2011; Dweep and Gretz, 2015) . The validated miRNA targets from miRWalk2 are collected via an automated text-mining search, which is the collated with data from other databases. Each gene set that was enriched for differentially expressed genes was then assessed for over-representation of miRNA targets using Fisher's exact test. Gene sets with a Benjamini-Hochberg adjusted p-value<0.05 were considered enriched for validated miRNA targets.
Finally, the expression levels of differentially expressed miRNAs and differentially expressed genes in the modules of interest were correlated to identify potentially miRNA-mRNA interaction partners. Correlations were calculated using Spearman's rank correlation, significant correlations (adjusted p-value<0.05) of greater than 0.7 and less than -0.7 were deemed potential interesting interaction partners.
Quantitative reverse-transcription PCR analysis
To evaluate the gene expression of Cathepsin H (CTSH), matrix metallopeptidase 17 (MMP17), matrix metallopeptidase 14 (MMP14), and interleukain-1 beta (IL1B), 2.5µg of total RNA was reverse-transcribed into cDNA using oligodT primers. PCR primers (Eurogentec, Belgium) were designed using the Universal ProbeLibrary of Roche (https://www.roche-applied-science.com) based on the reported cDNA sequences. The PCR master mix and data quantification was carried out in the same way as mentioned previously . The starting concentration of each product was divided by the starting concentration of the reference gene, eukaryotic translation elongation factor 1 alpha-1 (eEF1A1) and this ratio was compared between groups (Mann-Whitney U test); pvalue<0.05 was considered significant.
Connectivity map analysis
The connectivity map (CMap) uses cellular responses to perturbations to identify relationships between diseases and therapeutics (Subramanian et al., 2017) . The top 150 up-regulated and top 150 down-regulated genes from MTLE-HS sorted by adjusted p-value were fed into CMap. These were then compared to the CMap database that contains over one million gene expression signatures that are derived from L1000 high-throughput assay to identify perturbagens that give an opposing gene signature to that entered.
Results
RNA-Sequencing of MTLE brain tissue
RNA-Seq was performed on total RNA extracted from 22 MTLE subjects obtained at surgery and 11 non-epileptic post-mortem control subjects. Each sample was sequenced to a depth of 50 million paired-end reads. After quality J o u r n a l P r e -p r o o f assessment and filtering ~48 million paired-end reads remained per sample of which ~84% mapped concordantly to the human reference genome GRCh38. Dimensionality reduction of the gene expression profile using the tdistributed stochastic neighbor embedding (t-SNE) machine learning algorithm and subsequent plotting identified three major clusters of samples (Fig 1A) . Cortical samples clustered together regardless of disease or control status, while MTLE hippocampal samples (MTLE-HS) and control hippocampal samples produced two distinct, divergent clusters.
Two differential gene expression analyses were carried out; control cortex was compared to MTLE cortex (MTLE-ctx) and control hippocampus was compared to MTLE-HS. In line with t-SNE clustering analysis, only two differential expressed genes were identified when the control cortex was compared to the MTLE-ctx -transcription factor 23 (TCF23) and the uncharacterized non-coding RNA LOC101929719 (Fig 1B) . Both genes were upregulated in the MTLE-ctx. On the other hand, when the control hippocampus was compared to the MTLE-HS, large perturbations to the transcriptome profile were identified; 2780 genes were up-regulated and 2952 were downregulated ( Fig 1C) . The top 10 up-regulated and down-regulated genes (ranked by adjusted p-value) are listed in Table 2 . To validate the RNA-Seq data the genes CTSH, IL1B MMP17 and MMP14 were selected for analysis with RT-qPCR (Supp. Figure 1 ). In line with the RNA-Seq data the genes CTSH and IL1B were significantly upregulated (Mann-Whitney-U; p-value < 0.05) and MMP14 was significantly down-regulated (Mann-Whitney-U; pvalue < 0.05). While MMP17 appeared to be down-regulated, the change was not statistically significant.
A gene set enrichment analysis (GSEA) (see methods) was performed on the transcriptome profile generated from the RNA-Seq analysis of the control and MTLE-HS samples. 150 distinct pathways were significantly enriched (adjusted p-value < 0.05) and were also enriched for differentially expressed genes (Fisher's exact test, adjusted p-value < 0.05) (Supp. Table 1 ). The hippocampal transcriptome profile was enriched for pathways that included the immune system and immune cytokine signaling, MAPK family signaling cascades and negative regulation of the PI3K/AKT network (Fig 1D) .
J o u r n a l P r e -p r o o f Figure 1 . RNA-Seq analysis of post-mortem tissue from cortex and hippocampus of mesial temporal lobe epilepsy cases. a. t-Distributed stochastic neighbor embedding (t-SNE) two-dimensional projection of the whole transcriptome profile generated from each sample. Each point represents a different sample. Samples from the cortex cluster together regardless of disease state. For the samples isolated from the hippocampus there was separation by disease state. b. Volcano plot showing differential expression of genes between MTLE cortex (n=6) and control cortex (n=5). Two genes were found to be up-regulated and no genes were down-regulated. Gene were considered differentially expressed if the adjusted p-value < 0.05. c. Volcano plot showing differential expression of genes between MTLE hippocampus (n=6) and control hippocampus (n=16). 2780 genes were found to be up-regulated and 2952 genes were down-regulated. Gene were considered differentially expressed if the adjusted p-value < 0.05. d. Visualisation of the significantly enriched pathways that were also enriched for the number of differentially expressed genes (adjusted p-value < 0.05). Here only pathways with an adjusted p-value less than 0.01 are shown. Each node represents a different enriched pathway. Edges between nodes indicates shared genes in the pathway. J o u r n a l P r e -p r o o f
To delineate the potential cell-types perturbed in MTLE-HS pathology, we analyzed an independent dataset of single-cell RNA-Seq from neurons, microglia, oligodendrocytes and astrocytes taken from the healthy human brain (GSE67835) (Darmanis et al., 2015) . Genes from the single-cell RNA-Seq analysis were classified as microglia, oligodendrocyte, astrocyte and neuron specific based on expression values (greater than 10 read-counts in cell type of interest, less than 1 read count in all other cell-types). Of the 2780 genes up-regulated in MTLE-HS, 21
were specific to astrocytes, 9 to oligodendrocytes, 12 to neurons, and 41 to microglia (Supp. Table 2 ). Among the 2952 down-regulated genes in MTLE-HS, 41 were specific to neurons, 12 to astrocytes, 7 to microglia and 6 to oligodendrocytes (Supp. Table 2 ). Hypergeometric testing revealed that genes up-regulated in the hippocampus were significantly enriched for astrocytes (p < 0.01) and microglia (p < 0.01), while the down-regulated genes were significantly enriched for neurons (p < 0.01). J o u r n a l P r e -p r o o f Small RNA-Seq was performed on the same samples analyzed for RNA-Seq. Each sample was sequenced to a depth of ~20 million reads. After quality assessment and filtering, ~16 million reads remained, of which 88% were successfully mapped to the human reference genome GRCh38. Dimensionality reduction of the gene expression profile using the t-SNE algorithm and subsequent plotting identified two major clusters (Fig 2A) . Interestingly, whereas the standard RNA-Seq was reflective of brain region, the small RNA-Seq profiles reflected disease state, with both the MTLE-ctx and MTLE-HS clustering distinctly from the control cortex and hippocampus. This suggests that small RNAs reflect disease state more accurately than the mRNA fraction and are able to distinguish MTLE pathogenesis more readily from the control state.
Small RNA-Sequencing of MTLE brain tissue
In contrast to the standard RNA-Seq, small RNAs were identified as differentially expressed when the MTLE-ctx was compared to the control cortex. Overall, there were 66 small RNAs that were up-regulated and 142
down-regulated small RNAs (Fig 2B) . The top 10 up-regulated and down-regulated small RNAs (ranked by adjusted p-value) are listed in Table 3 . When MTLE-HS was compared to control hippocampus there were 218 upregulated and 448 were down-regulated small RNAs (Fig 2C) . Next, the biotypes of the differentially expressed small RNAs were assessed, the most common biotype of differentially expressed small RNAs in both the MTLE-HS and MTLE-ctx was small nuclear RNAs, followed by miRNAs (Fig 2D-E) . Finally, the overlap of miRNAs and other small non-coding RNAs from hippocampus and cortex were analysed (Supp. Figure 2) . Of the differentially expressed miRNAs in the MTLE-HS, only 9% of up-regulated miRNAs and 16% of down-regulated miRNAs were also differentially expressed in the MTLE cortex. By contrast, among other small RNA species, 44% of those upregulated and 32% of those down-regulated in the MTLE-HS were similarly up-or down-regulated in the MTLEctx. This result suggests that the expression patterns of the other small non-coding RNAs, including snoRNAs and snRNAs, are more conserved across the regions of brain of patients with MTLE than the expression changes of miRNAs or mRNAs.
J o u r n a l P r e -p r o o f Figure 2 . Small RNA-Seq analysis of post-mortem tissue from cortex and hippocampus of mesial temporal lobe epilepsy cases. a. t-SNE two-dimensional projection of the small RNA expression profile generated from each sample. Each point represents a different sample. In contrast to the RNA-Seq data samples cluster by disease state rather than brain region. b. Volcano plot showing differential expression of small RNAs between MTLE hippocampus (n=6) and control hippocampus (n=16). 66 small RNA were found to be up-regulated and 142 small RNAs were down-regulated. Small RNAs were considered differentially expressed in the adjusted p-value < 0.05. c. Volcano plot showing differential expression of small RNAs between MTLE hippocampus (n=6) and control hippocampus (n=16). 218 small RNA were found to be up-regulated and 448 small RNAs were down-regulated. Small RNAs were considered differentially expressed in the adjusted p-value < 0.05. d. Biotypes of differentially expressed small RNAs in the cortex. Small nuclear RNAs made up the majority of the differentially expressed small RNAs, followed by small nucleolar RNAs, and miRNAs. e. Biotypes of differentially expressed small RNAs in hippocampus. Small nuclear RNAs made up the majority of the differentially expressed small RNAs, followed by small nucleolar RNAs, and miRNAs J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f
Bioinformatic integration of small RNA-Sequencing and RNA-Sequencing data
To identify key miRNAs that may regulate pathogenic or altered pathways in the hippocampus of MTLE patients, each of the 150 enriched pathways from the GSEA were assessed for over-representation of validated miRNA targets of the differentially expressed miRNAs. Of the enriched pathways, 36 were enriched for validated miRNA targets (Fisher' s Exact test, adjusted p-value < 0.05) (Fig 3) . Next, we analyzed individual correlations between miRNAs and their validated pathway targets to identify potentially important pairs. Among the miRNAs of interest, let-7b-3p and let-7c-3p had the strongest negative correlations with differentially expressed genes (Spearman's rank correlation <-0.7, adjusted p<0.05). Expression of let-7b-3p was negatively correlated with five differentially expressed genes (Spearman's rank correlation < -0.7, adjusted p-value<0.05) and positively correlated with eight differentially expressed genes (Spearman's rank correlation > 0.7, adjusted p-value<0.05) (Supp. Table 3 ). Let-7c-3p was negatively correlated with ten differentially expressed genes (Spearman's rank correlation < -0.7, adjusted p-value<0.05) and positively correlated with 20 differentially expressed genes (Spearman's rank correlation > 0.7, adjusted p-value<0.05) (Supp. Table 3 ).
J o u r n a l P r e -p r o o f
Furthermore, let-7b-3p and let-7c-3p, were predicted as major regulators of 15 and 19 different pathways, respectively, of which 12 pathways were common to both miRNAs. Of particular interest were the negative correlations between let-7b-3p and Trio Rho Guanine Nucleotide Exchange Factor (TRIO) and Prostaglandin E Synthase 2 (PTGES2), and let-7c-3p and DEAD-Box Helicase 41 (DDX41), SWI/SNF Related Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4) and Lysine Methyltransferase 2D (KMT2D) (Fig. 4) . Each of these genes were present in the inflammation and immune response related enriched pathways. 
Connectivity map analysis
The up-regulated and down-regulated gene lists from the MTLE-HS were analyzed using the connectivity map (CMap) (see methods) to identify compounds that would give rise to a gene signature that opposes the gene J o u r n a l P r e -p r o o f signature observed in MTLE-HS. The top five compounds identified included dictamnine, which has diverse biological activities, such as antifungal, antibacterial, vascular-relaxing, antiplatelet aggregation, anti-hypertension and anti-tumor activities, the MEK inhibitor PD-0325901, the MTOR inhibitor deforolimus, the anti-inflammatory compound celastrol, and the estrogen receptor agonist dairylpropionitrile. These compounds are already approved for use in humans and as such could be repurposed for use in the treatment of MTLE.
Discussion
We found striking differences in the RNA and small RNA transcriptome profiles in the hippocampus of patients with MTLE compared to control hippocampus. The RNA transcriptome from MTLE patients showed 2780 upregulated genes and 2952 down-regulated genes compared to controls. We identified an enrichment 150 pathways within the transcriptome profile of the MTLE hippocampus, including immune function, cytokine signaling, MAPK signaling and PI3K/AKT network. In contrast, the neocortical expression patterns were similar among patients and controls with only two genes up-regulated in MTLE. Interestingly, there were marked differences in small RNA expression in both neocortex and hippocampus of MTLE patients compared to controls. In the MTLE-ctx, 66 small
RNAs were up-regulated and 142 were down-regulated. In the MTLE-HS, 218 small RNAs were up-regulated and 448 were down-regulated. Integration of the small RNA and RNA transcriptome profiles of the MTLE-HS identified 36 significantly enriched pathways that may be regulated by miRNAs, including many immune response and inflammation related pathways.
We observed distinct differences between the clustering of the RNA and the small RNA transcription profiles. While RNAs could be used to clearly define the brain region from which the sample was extracted, the small RNA transcriptome profile clustered by disease state, entirely independent of brain region. For both the MTLE-ctx and the MTLE-HS the most common biotype of differentially expressed small RNAs was small nuclear RNAs, followed by miRNAs and then small nucleolar RNAs. Interestingly, expression changes in the other small non-coding RNA species were relatively more conserved between the hippocampus and neocortex when compared to miRNAs, which showed greater regional divergence. These findings suggest that small non-coding RNAs may be involved in the initial underlying molecular pathogenesis of MTLE, or the brain's compensatory changes to suppress epileptogenesis and seizures. While small nucleolar RNAs have been implicated in cancer (Liao et al., 2014; Mei et al., 2012) and small nuclear RNAs in Alzheimer's disease (Bai et al., 2013) these elements have never been investigated in terms of MTLE. The results presented here suggest that these understudied elements of the J o u r n a l P r e -p r o o f transcriptome require more attention for disease modifying roles in MTLE. Further studies to determine whether these changes are part of the pathology or compensatory changes in MTLE could result in the development of new therapeutic tools.
In the present study, let-7b-3p and let-7c-3p were predicted as regulators of 15 and 19 different enriched pathways respectively. This suggests that these miRNAs may act as critical regulators of the MTLE transcriptional networks. For this analysis only experimentally validated miRNA-mRNA from a single database were assessed. It is possible that by miRNAs from the lethal-7 (let-7) family were among the first miRNAs to be discovered and are evolutionarily conserved across various animal species (Lee et al., 2016) . Previously, let-7b was shown to regulate cell proliferation and differentiation in the cortex of mice during development (Zhao et al., 2010) . Knock-down of let-7b resulted in enhanced proliferation of neural stem cells, while over-expression of let-7b decreases proliferation and accelerates neuronal differentiation (Zhao et al., 2010) . Let-7b has also been shown to interact with the long non-coding RNA H19 (Han et al., 2018b) . Inhibition of let-7b via H19 contributes to apoptosis of hippocampal neurons in a rat model of MTLE (Han et al., 2018a) . The function and expression of let-7c in the epileptogenic brain is less well studied. Overexpression of let-7c in human stem cells leads to morphological as well as functional deficits including impaired neuronal morphologic development, synapse formation and synaptic strength, as well as a marked reduction of neuronal excitability (McGowan et al., 2018) . In one study let-7c expression did not change in the hippocampus of MTLE patients and in the cortex of FCD patients when compared to controls (Srivastava et al., 2017) . However, in another study let-7c was found to be increased in serum of drug-responsive MTLE patients compared to drug-resistant MTLE patients (Wang et al., 2015) . Both let-7b-3p and let-7c-3p remain interesting targets for further investigation in their role of regulation of the MTLE transcriptional network and whether they possess disease modifying properties.
Based on alterations to the mRNA transcriptome profile five compounds were identified that could counteract the gene expression changes identified in MTLE-HS: the MEK inhibitor PD-032590, the mTOR inhibitor deforolimus, the anti-inflammatory celastrol, the estrogen receptor agonist diarylpropionitrile, and dictamnine.
Hyper-activation of the mTOR pathway is implicated in the pathogenesis of epilepsy associated with MTLE, tuberous sclerosis complex, cortical dysplasia and some genetic epilepsies (e.g., DEPDC5) (Crino, 2015; Wong, 2013) . Since the mTOR and MEK pathways are interconnected, hyper-activation in MEK may also facilitate J o u r n a l P r e -p r o o f epileptogenesis and seizures (Conciatori et al., 2018) . The mTOR pathway is suggested to be an anti-epileptogenic target (Galanopoulou et al., 2012) , and the mTOR inhibitor everolimus is currently used in the clinic as adjunctive therapy for patients with tuberous sclerosis complex (Franz et al., 2018; French et al., 2016) . The role of inflammation in a spectrum of experimental and human epilepsies is well established and several neuroinflammatory pathways have been identified as novel treatment targets for epilepsy (van Vliet et al., 2018) . The effects of estrogens on seizures is less clear (Velíšková et al., 2010) . For decades, estrogens were considered proconvulsant, however, recent studies show that estrogens can be either excitatory or inhibitory. The estrogen receptor agonist diarylpropionitrile had anti-seizure effects in the pentylenetetrazole-induced seizures (Frye et al., 2009 ). However, estrogen can be proconvulsant in animals and humans (Scharfman and MacLusky, 2006) . Finally, dictamnine is a furoquinoline antibiotic for which little is known about its potential central nervous system effects; however, it inhibits lipopolysaccharide-induced nitric oxide production in vitro and may have anti-oxidant and antiinflammatory effects in the brain (Yoon et al., 2012) . While this approach has previously been used to identify potential drug candidates for the treatment of cancer of which many have been validated in vitro (Musa et al., 2018) , whether these compounds could be disease modifying for individuals with refractory epilepsy requires further investigation.
A potential limitation of the presented study was the use of post-mortem brain tissue for the controls versus surgical resected material for the MTLE cases. Due to technical and ethical issues the use of post-mortem tissue as controls is standard practice in many human brain transcriptome studies. The general assumption is that sourcing RNA from brain tissue from two fundamentally different biological stages would result in the identification of transcriptional changes that reflect these stages rather than the disease of interest. Interestingly, the results presented here (Figure 2b ) suggest that this issue may be overstated. Indeed, when post-mortem brain tissue of the cortex was compared to surgical resected material from the cortex, only two differentially expressed genes were identified.
Further, clustering of the transcriptional profiles of both tissue sources revealed that the profiles were similar. These results are in-line with what is known about the pathology of the cortex in MTLE. While, this study provides preliminary evidence that there are only minor transcriptional alterations when post-mortem brain tissue is compared to surgical tissue a more comprehensive and systematic study is required that analyses different RNA species, such as non-coding RNAs, across different brain regions. However, this result does suggest that the alterations in the small RNA profiles of the MTLE-ctx are likely to be disease related. It also must be noted that the MTLE material J o u r n a l P r e -p r o o f used for this study was taken from individuals who had been experiencing seizures for multiple years (range: 7-52 years), further no information on time since last seizure prior to operation was available, this makes it difficult delineate and attribute the identified transcriptional changes to underlying epileptogenic changes or as a consequence of seizure activity. Subsequent in vivo studies or in vitro studies would be required to elucidate which of the identified transcriptional changes can be attributed to epileptogenic events or as a symptom of seizure activity, and to further assess if any of the novel changes identified here could be utilized as a molecular target for treatment of MTLE. Finally, amongst the samples chosen for this study there was a selection bias towards male samples, this was due to the genders of the available of samples. This potential confounder was considered; however, clustering of samples showed no difference in the overall RNA-Seq and small RNA-Seq transcriptome profile between the female and male samples and as such any differences introduced by gender were considered minimal.
Conclusions
This study constitutes the most systematic transcriptomic analysis of MTLE brain tissue to date, by analyzing both the expression profiles of RNA and small RNA in parallel we provide new insights in MTLE pathogenesis. The transcriptome profile generated from RNA-Seq confirmed key pathogenic pathways activated, along with neuronal loss and activation of astrocytes and microglia in the hippocampus of MTLE patients. Through the integration of both RNA-Seq and small RNA-Seq the miRNAs let-7b-3p and let-7c-3p were identified as potential key regulators of multiple pathways related to MTLE pathology. Most interestingly, this study has identified a potential key role for other small non-coding RNA species, such as small nucleolar RNAs and small nuclear RNAs, in the pathogenesis of MTLE. These understudied elements of the transcriptome have emerging roles in other diseases, including cancer and Alzheimer's disease, but are yet to receive such attention in MTLE and related pathologies.
